Product Name: CDK2 (162-171) pT165+pY168
Product Number: PE-04ASM85
| Size: | 200 µg | Price: | 17.00 | |
| 1 mg | $US | 34.00 |
Peptide Name: CDK2 (162-171) pT165+pY168
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. T165 and Y168 phosphorylation is predicted to be inhibitory for phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: EVV-pT-LW-pY-RAP
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. T165 and Y168 phosphorylation is predicted to be inhibitory for phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: EVV-pT-LW-pY-RAP
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1566.6 Da
Peptide Purity Percent after Synthesis and Purification: 86.6*
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Storage Stability: Not stable
Peptide Purity Percent after Synthesis and Purification: 86.6*
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Storage Stability: Not stable
Scientific Background: CDK2 is a protein-serine/threonine kinase of the CMGC group and CDK family. It is essential for meiosis, yet not essential for mitosis, although it is involved in cell cycle control. CDK2 has been observed to phosphorylate CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, and EZH2. Involved in the control of the cell cycle. Interacts with cyclins A, B1, B3, D, or E. Activity of CDK2 is maximal during S phase and G2. Mutations resulting in reduced CAK phosphorylation at the T160 activating phosphosite include K9F, and K88E + K89V, while a L166R mutation results in reduced CAK phosphorylation and lower protein-serine/threonine phosphotransferase activity. Phosphorylation at Y179 increases phosphotransferase activity and interaction with CCNA2 (Cyclin A2). CCNA2 stimulates the catalytic activity of CDK2. Phosphorylation at T14 and Y15 inhibits phosphotransferase activity.
© Kinexus Bioinformatics Corporation 2017